gastric inhibitory polypeptide

Overview

Gastric inhibitory polypeptide, more commonly referred to as glucose-dependent insulinotropic polypeptide (GIP), is a gut-derived peptide hormone and protein target involved in the regulation of glucose metabolism. It is one of the principal incretin hormones released from the intestine in response to nutrient intake, and it contributes to the postprandial insulin response through glucose-dependent stimulation of pancreatic insulin secretion. Because of this physiology, GIP has long been of interest in metabolic disease research, particularly in type 2 diabetes and obesity.

In contemporary biomedical research, GIP is also important as a pharmacologic target. It is being incorporated into multi-agonist strategies alongside glucagon-like peptide-1 (GLP-1) and glucagon signaling to improve metabolic outcomes. This has made GIP relevant not only to endocrine physiology but also to the development of newer anti-obesity and antidiabetic therapies, including tirzepatide and retatrutide.

Focus of Latest Publications

Recent publications have focused on GIP as both a physiological hormone and a pharmacologic target in metabolic disorders. One major theme is the use of GIP receptor agonism in combination therapies for type 2 diabetes and obesity. In the SURPASS-CVOT trial context, tirzepatide was described as a dual incretin agonist targeting the glucose-dependent insulinotropic polypeptide and GLP-1 receptors, and it was reported to be non-inferior to dulaglutide for the primary composite cardiovascular outcome in people with type 2 diabetes and atherosclerotic cardiovascular disease. This places GIP-targeted therapy within the broader cardiovascular and renal risk-management landscape for diabetes.

Another study examined the effects of a 6-week subcutaneous infusion of native GIP alone or as an add-on to semaglutide in people with type 2 diabetes. The publication explicitly notes that the long-term glycaemic effects of GIP remain unclear, underscoring that the hormone is still being evaluated for its standalone and combination effects in human metabolic regulation. The use of semaglutide in this setting reflects ongoing interest in how GIP interacts with GLP-1-based therapy, especially in patients with diabetes who may already be receiving incretin-based treatment.

Broader reviews in the recent literature position GIP among a group of gut-pancreatic peptides of therapeutic interest, alongside glucagon, amylin, and peptide YY (PYY), because of their distinct pharmacological benefits and promise in metabolic disorders. This framing reflects the shift from single-hormone approaches toward multi-agonist therapies. In this context, GIP is not only a target in diabetes treatment but also part of a larger strategy for addressing obesity, metabolic dysfunction–associated steatotic liver disease, and related conditions.

Additional publications reinforce this therapeutic trend. tirzepatide was discussed in real-world evidence for recurrent weight gain after bariatric procedures, where it was characterized as a dual agonist of the GIP and GLP-1 receptors and described as promising for obesity treatment, although data in post-bariatric or endoscopic bariatric therapy settings remain limited. Similarly, retatrutide was described in the design of the TRANSCEND-CKD trial as an agonist of the GIP, GLP-1, and glucagon receptors, with prior evidence of reduced weight and hemoglobin A1c in individuals with obesity and type 2 diabetes. Together, these studies show that GIP is being investigated in combination with semaglutide, dulaglutide, and other metabolic therapies, and in clinical settings ranging from basal insulin-treated patients to obesity and chronic kidney disease populations.

Key Publications

NEWMay A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. (The lancet. Diabetes & endocrinology, 2026, PMID 42114520): "In the SURPASS-CVOT trial, tirzepatide, a dual incretin agonist that targets the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, was shown to be non-inferior to dulaglutide for the primary composite cardiovascular outcome in people with type 2 diabetes and atherosclerotic cardiovascular disease."
May Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial. (The lancet. Diabetes & endocrinology, 2026, PMID 42173109): "The long-term glycaemic effects of glucose-dependent insulinotropic polypeptide (GIP) remain unclear."
Jun The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. (Bioscience reports, 2026, PMID 42307179): "Gut-pancreatic peptides such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY (PYY) are of particular interest due to their distinct pharmacological benefits and therapeutic promise in metabolic disorders."
Jun Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin. (The Journal of clinical endocrinology and metabolism, 2026, PMID 41604435): "(including glucose-dependent insulinotropic polypeptide [GIP], glucagon, and insulin)."
Jun Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. (Obesity surgery, 2026, PMID 42247124): "Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown promising results in obesity treatment, but data regarding its use in post BS or EBT recurrent weight gain are limited."
May Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026, PMID 41160422): "Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D)."